Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial

Authors: Kneebone, Andrew ^*, Fraser-Browne, Carol, Duchesne, Gillian M, Fisher, Richard, Frydenberg, Mark, Herschtal, Alan, Williams, Scott G, Brown, Chris, Delprado, Warick, Haworth, Annette, Joseph, David J, Martin, Jarad M, Matthews, John H L, Millar, Jeremy L, Sidhom, Mark, Spry, Nigel, Tang, Colin I, Turner, Sandra, Wiltshire, Kirsty L, Woo, Henry H, Davis, Ian D, Lim, Tee S, Pearse, Maria

Source: In The Lancet Oncology October 2020 21(10):1331-1340

Extracting tumour prognostic factors from a diverse electronic record dataset in genito-urinary oncology

Authors: Khor, Richard C., Nguyen, Anthony, O’Dwyer, John, Kothari, Gargi, Sia, Joseph, Chang, David, Ng, Sweet Ping, Duchesne, Gillian M., Foroudi, Farshad

Source: In International Journal of Medical Informatics January 2019 121:53-57

Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

Authors: Duchesne, Gillian M ^*, Woo, Henry H, King, Madeleine, Bowe, Steven J, Stockler, Martin R, Ames, Alice, D'Este, Catherine, Frydenberg, Mark, Loblaw, Andrew, Malone, Shawn, Millar, Jeremy, Tai, Keen Hun, Turner, Sandra

Source: In The Lancet Oncology September 2017 18(9):1192-1201

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

Authors: Duchesne, Gillian M, Woo, Henry H, Bassett, Julie K, Bowe, Steven J, D'Este, Catherine, Frydenberg, Mark, King, Madeleine, Ledwich, Leo, Loblaw, Andrew, Malone, Shawn, Millar, Jeremy, Milne, Roger, Smith, Rosemary G, Spry, Nigel, Stockler, Martin, Syme, Rodney A, Tai, Keen Hun, Turner, Sandra

Source: In The Lancet Oncology June 2016 17(6):727-737

Validation of a radiobiological model for low-dose-rate prostate boost focal therapy treatment planning

Authors: Haworth, Annette, Williams, Scott, Reynolds, Hayley, Waterhouse, David, Duchesne, Gillian M., Bucci, Joseph, Joseph, David, Bydder, Sean, Ebert, Martin

Source: In Brachytherapy November-December 2013 12(6):628-636

High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer

Authors: Zwahlen, Daniel R., Andrianopoulos, Nick, Matheson, Bronwyn, Duchesne, Gillian M., Millar, Jeremy L.

Source: In Brachytherapy 2010 9(1):27-35

Online Kidney Position Verification Using Non-Contrast Radiographs on a Linear Accelerator with on Board KV X-Ray Imaging Capability

Authors: Willis, David J., Kron, Tomas, Hubbard, Patricia, Haworth, Annette, Wheeler, Greg, Duchesne, Gillian M.

Source: In Medical Dosimetry 2009 34(4):293-300

Urethral stricture following high dose rate brachytherapy for prostate cancer

Authors: Sullivan, Lisa, Williams, Scott G., Tai, Keen Hun, Foroudi, Farshad, Cleeve, L., Duchesne, Gillian M.

Source: In Radiotherapy and Oncology 2009 91(2):232-236

Tolerability and outcomes of curative radiotherapy in patients aged 85 or more years

Authors: Khor, Richard C, Bressel, Mathias, Tedesco, Jo, Tai, Keen Hun, Ball, David L, Duchesne, Gillian M, Farrugia, Helen, Yip, Wai Kuan, Foroudi, Farshad

Source: Medical journal of Australia. 202(3):153-155

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100134801533.0x000001&indx=1&recIds=ETOCvdc_100134801533.0x000001

A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy?

Authors: Tang, Johann I., Williams, Scott G., Tai, Keen Hun, Dean, Joanne, Duchesne, Gillian M.

Source: In Brachytherapy 2006 5(4):256-261

Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: A report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group

Authors: Gogna, Nirdosh Kumar, Matthews, John H.L., Turner, Sandra L., Mameghan, Heidi, Duchesne, Gillian M., Spry, Nigel, Berry, Martin P., Keller, Jacqui, Tripcony, Lee

Source: In Radiotherapy and Oncology 2006 81(1):9-17

Effective and well tolerated: where do these drugs fit now?

Authors: Duchesne, Gillian M

Source: Lancet oncology. 20(4):469-470

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100111558433.0x000001&indx=1&recIds=ETOCvdc_100111558433.0x000001

Impact of selection of post-implant technique on dosimetry parameters for permanent prostate implants

Authors: Haworth, Annette, Ebert, Martin, St. Clair, Shaun, Carey, Brendan M., Flynn, Anthony, Bottomley, David M., Duchesne, Gillian M., Joseph, David, Ash, Daniel

Source: In Brachytherapy 2005 4(2):146-153

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy.

Authors: Stensland, Kristian D, Devasia, Theresa, Caram, Megan E V, Chapman, Christina, Zaslavsky, Alexander, Morgan, Todd M, Hollenbeck, Brent K, Sparks, Jordan B, Burns, Jennifer, Vedapudi, Varsha, Duchesne, Gillian M, Tsodikov, Alexander, Skolarus, Ted A

Source: JNCI Cancer Spectrum; Jun2022, Vol. 6 Issue 3, p1-7, 7p

Subject Terms: ANDROGEN deprivation therapy, PROSTATE cancer

Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy

Authors: Williams, Scott G. ^*, Millar, Jeremy L., Duchesne, Gillian M., Dally, Michael J., Royce, Peter L., Snow, Ross M.

Source: In Radiotherapy and Oncology 2004 73(1):33-38

Testing the Assessment of New Radiation Oncology Technology and Treatments framework using the evaluation of post-prostatectomy radiotherapy techniques.

Authors: Duchesne, Gillian M¹, Haworth, Annette¹, Bone, Eric², Carter, Hannah³, Ebert, Martin A^4,5, Gagliardi, Frank⁶, Gibbs, Adrian⁷, Hornby, Colin¹, Martin, Andrew³, Sidhom, Mark⁸, Wood, Maree⁹, Jackson, Michael¹⁰

Source: Journal of Medical Imaging & Radiation Oncology. Feb2016, Vol. 60 Issue 1, p129-137. 9p.

Subject Terms: *TREATMENT effectiveness, *RADIOTHERAPY treatment planning, *RADIATION dosimetry, *PROSTATECTOMY, *QUALITY of life, *MEDICAL economics, *PROSTATE tumors treatment, *COMPARATIVE studies, *RESEARCH methodology, *MEDICAL cooperation, *PROSTATE tumors, *RADIATION doses, *RADIATION injuries, *RADIOTHERAPY, *RESEARCH, *SURVIVAL analysis (Biometry), *SURVIVAL, *EVALUATION research, *DISEASE incidence, *ECONOMICS, *PREVENTION

Geographic Terms: AUSTRALIA, NEW Zealand

Trans Tasman Radiation Oncology Group: Development of the Assessment of New Radiation Oncology Technology and Treatments ( ANROTAT) Framework.

Authors: Duchesne, Gillian M^1,2,3, Grand, Mel⁴, Kron, Tomas^1,3,5, Haworth, Annette^1,2, Corry, June^1,2, Jackson, Michael⁶, Ng, Michael⁷, Besuijen, Deidre⁴, Carter, Hannah E⁸, Martin, Andrew⁸, Schofield, Deborah^8,9, Gebski, Val⁸, Torony, Joan⁴, Kovacev, Olga⁴, Amin, Rowena¹⁰, Burmeister, Bryan¹¹

Source: Journal of Medical Imaging & Radiation Oncology. Jun2015, Vol. 59 Issue 3, p363-370. 7p.

Subject Terms: *ONCOLOGY, *RADIOTHERAPY, *BIOMETRICIANS, *MEDICAL economics, *PHYSIOLOGICAL effects of radiation

Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study

Authors: Duchesne, Gillian M, Dowling, Caroline, Frydenberg, Mark, Joseph, David, Gogna, N.Kumar, Neerhut, Greg, Roberts, Sydney, Spry, Nigel, Turner, Sandra, Woo, Henry

Source: In Urology 2003 61(1):179-183

Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy

Authors: Williams Scott, Chander Sarat, Leahy Mary, Rolfo Aldo, Kron Tomas, Fox Chris, Thomas Jessica, Gill Suki, Tai Keen Hun, Duchesne Gillian M, Foroudi Farshad

Source: Radiation Oncology, Vol 6, Iss 1, p 145 (2011)

Subject Terms: Acute toxicity, image-guided radiotherapy, prostate cancer, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.ro-journal.com/content/6/1/145; https://doaj.org/toc/1748-717X

Access URL: https://doaj.org/article/0ff56e18932e48b39c6a9e2430c63270

The ' Timing of Androgen- Deprivation therapy in incurable prostate cancer' protocol ( TOAD) - where are we now? Synopsis of the Victorian Cooperative Oncology Group PR 01-03 and Trans- Tasman Radiation Oncology Group 03.06 clinical trial.

Authors: Duchesne, Gillian M.¹, Woo, Henry H.²

Source: BJU International. Nov2014 Supplement, Vol. 114, p9-12. 4p.

Subject Terms: *PROSTATE cancer, *RADIOTHERAPY, *CLINICAL trials, *QUALITY of life, *RADIOLOGY

Geographic Terms: AUSTRALIA, NEW Zealand